Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 4/20 | 0.46 |
| ▸ | SSTR4 | P31391 | 13/20 | 0.43 |
| ▸ | SSTR1 | P30872 | 7/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20068980 | 0.87 | RET (0.47) | RETSSTR4SSTR1 | |
| SCHEMBL20068976 | 0.87 | SSTR4 (0.48) | RETSSTR4SSTR1 | |
| SCHEMBL20069600 | 0.85 | RET (0.49) | RETSSTR4SSTR1 | |
| SCHEMBL21651925 | 0.85 | RET (0.46) | RETMEN1KMT2ACNR1 | |
| SCHEMBL20147664 | 0.85 | RET (0.45) | RETMEN1KMT2ACNR1 | |
| SCHEMBL20068949 | 0.84 | SSTR4 (0.51) | SSTR4SSTR1MEN1KMT2A | |
| SCHEMBL20147997 | 0.84 | RET (0.44) | RETMEN1KMT2ACNR1 | |
| SCHEMBL20068977 | 0.83 | SSTR4 (0.53) | RETSSTR4SSTR1 | |
| SCHEMBL20068866 | 0.78 | SSTR4 (0.49) | RETSSTR4CNR1 | |
| SCHEMBL20068948 | 0.77 | ALDH1A1 (0.48) | RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-05-16 | — | — | US | disclosed |
| WO-2018071454-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ANDREWS STEVEN W (US) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | RET 1/4885SSTR4 2604/4885SSTR1 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.